Caplyta

Active Ingredient(s): Lumateperone
FDA Approved: * December 20, 2019
Pharm Company: * INTRA-CELLULAR THERAPIES INC
Category: Antipsychotic

Lumateperone, sold under the brand name Caplyta, is a medication used for the treatment of schizophrenia and bipolar depression.[1] It is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb.[2] The most common side effects include sleepiness and dry mouth.[3] Lumateperone was approved for medical use in the United States in December 2019,[3][4] and becam... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Caplyta 42 mg Oral Capsule
NDC: 72060-142
Labeler:
Intra-cellular Therapies, Inc